Intersect ENT Inc is a drug device company that develops products for patients with ear, nose, and throat conditions. The firm’s key commercial products are the Propel brand of steroid-releasing implants, which are used in patients undergoing surgery for chronic sinusitis. These implants are placed into the ethmoid sinuses after surgery and are designed to expand and hold open the surgically enlarged sinus while releasing an anti-inflammatory steroid. After roughly 30 days, the implant is fully absorbed into the body. Intersect ENT generates the vast majority of its revenue in the United States.